Additionally, EZH2 was also found to bind to the Euchromatic histone-lysine N-methyltransferase 2 (EHMT2) driving cisplatin and paclitaxel resistance in NSCLC cells (Zhang Q. et al., 2024). Here, EHMT2 is linked to non-small cell lung carcinoma.